We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Shimadzu Highlights LC-MS/MS Platforms at ADLM 2026

By LabMedica International staff writers
Posted on 30 Jul 2026

Shimadzu Scientific Instruments is showcasing liquid chromatography–tandem mass spectrometry (LC-MS/MS) solutions at the ADLM 2026 Clinical Expo in Anaheim, California. More...

At booth 1553, the company is presenting the Nexera QX Multiplex LC-MS/MS system and CLAM-2040 Automated Sample Preparation Module, which are designed to streamline sample preparation, increase throughput, and improve workflow consistency.

The Nexera QX Multiplex LC-MS/MS system uses multiple alternating sample-introduction streams to maintain continuous mass spectrometer operation. Its Multiple Stream technology eliminates waiting periods for column equilibration and system flushing, supporting faster analysis with low carryover.

Dedicated QX Solution software provides centralized control of the system’s multiple UHPLC streams and mass spectrometer. The software automates valve switching, gradient control, injection timing, and flushing, while online two-dimensional liquid chromatography supports automated trap-and-elute sample preparation.

Shimadzu is also displaying the CLAM-2040, which automates sample preparation for routine LC-MS analyses. By reducing manual handling, the system is designed to minimize operator error, improve result reproducibility, and enable continuous testing, including during nights and weekends.

Under optimized conditions, the CLAM-2040 and an LC-MS/MS system can deliver one result every 2.6 minutes. Laboratories can continuously add specimens and consumables, prioritize urgent samples without interrupting a batch, and use either established assays or internally developed methods.

The configurable platform can be adapted for future upgrades and paired with high-resolution quadrupole time-of-flight mass spectrometry for broader screening applications. Through its ADLM exhibit, Shimadzu is highlighting automated and multiplexed technologies intended to improve productivity across clinical mass spectrometry workflows.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Manual Pipetting Aid
Pipette Controllers macro
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.